Penetration and biological effects of topically applied cyclosporin A nanoparticles in a human skin organ culture inflammatory model

Experimental Dermatology

Volumn 21, Issue 12, 2012, Pages 938-943

  Frušić Zlotkin, Marina ^a   Soroka, Yoram ^a   Tivony, Ran ^a   Larush, Liraz ^a   Verkhovsky, Lilian ^a   Brégégère, François Menahem ^a   Neuman, Rami ^b   Magdassi, Shlomo ^a   Milner, Yoram ^a,c  

^a HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^b HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^c Tamar Regional Council   (Israel)

Author keywords

Cyclosporin A; Cytokines; Nanoparticles; Psoriasis; Skin organ culture

Indexed keywords

ANTIPSORIASIS AGENT; BACTERIUM LIPOPOLYSACCHARIDE; CYCLOSPORIN A; CYTOKINE; EPIDERMAL GROWTH FACTOR; INTERLEUKIN 1BETA; INTERLEUKIN 20; INTERLEUKIN 23; INTERLEUKIN 6; INTERLEUKIN 8; NANOPARTICLE; POLYCAPROLACTONE; RESAZURIN;

ARTICLE; CELL VIABILITY; CONTROLLED STUDY; CYTOKINE RELEASE; CYTOTOXICITY; DERMATITIS; DRUG ABSORPTION; DRUG EFFICACY; DRUG PENETRATION; DRUG SYNTHESIS; FLUORESCENCE; HUMAN; HUMAN TISSUE; IMMUNODETECTION; SKIN PENETRATION; ZETA POTENTIAL;

ADMINISTRATION, TOPICAL; ADOLESCENT; ADULT; CELL SURVIVAL; CYCLOSPORINE; CYTOKINES; DERMATITIS; DERMATOLOGIC AGENTS; EMULSIONS; FEMALE; HUMANS; MIDDLE AGED; NANOPARTICLES; ORGAN CULTURE TECHNIQUES; PSORIASIS; SKIN; YOUNG ADULT;

EID: 84869993977     PISSN: 09066705     EISSN: 16000625     Source Type: Journal    
DOI: 10.1111/exd.12051     Document Type: Article

References (29)

1. Berth-Jones J. J Dermatolog Treat 2005: 16: 258-277.
2. Griffiths C E M, Powles A V, Baker B S et al. Lancet 1987: 329: 806.
3. Powles A V, Baker B S, McFadden J et al. Lancet 1988: 331: 537.
4. Vickers A E M, Biggi W A, Dannecker R et al. Life Sci 1995: 57: 215-224.
5. Schulze H J, Mahrle G, Steigleder G K. Br J Dermatol 1990: 122: 113-114.
6. Cevc G, Vierl U. J Controlled Release 2010: 141: 277-299.
7. Liu H, Li S, Wang Y et al. Int J Pharm 2006: 311: 182-186.
8. Lopes L B, Collett J H, Bentley M V. Eur J Pharm Biopharm 2005: 60: 25-30.
9. Lopes L B, Lopes J L C, Oliveira D C R et al. Eur J Pharm Biopharm 2006: 63: 146-155.
10. Jibry N, Heenan R K, Murdan S. Pharm Res 2004: 21: 1852-1861.
11. Prasad V, Kumar N, Mishra P R. Drug Deliv 2007: 14: 75-85.
12. Guo J, Ping Q, Sun G et al. Int J Pharm 2000: 194: 201-207.
13. Verma D D, Fahr A. J Control Release 2004: 97: 55-66.
14. Liu H, Li S, Pan W et al. Int J Pharm 2006: 326: 32-38.
15. Liu H Z, Wang Y J, Li S M. PDA J Pharm Sci Technol 2010: 64: 191-199.
16. Calvo P, Sánchez A, Martínez J et al. Pharm Res 1996: 13: 311-315.
17. Stenderup K, Rosada C, Alifrangis L et al. Exp Dermatol 2011: 20: 441-444.
18. Portugal-Cohen M, Soroka Y, Frušić-Zlotkin M et al. Exp Dermatol 2011: 20: 749-755.
19. Soroka Y, Frušić-Zlotkin M, Verkhovsky L et al. EGF and LPS-stimulated skin organ culture displays inflammatory and psoriatic features: a model for biological evaluation of topical drugs. Under revision.
20. Margulis-Goshen K, Donio-Netivi H, Major D T et al. J Colloid Interface Sci 2010: 342: 283-292.
21. Palomino J C, Martin A, Camacho M et al. Antimicrob Agents Chemother 2002: 46: 2720-2722.
22. Wilmer J L, Burleson F G, Kayama F et al. J Invest Dermatol 1994: 102: 915-922.
23. Groves R W, Rauschmayr T, Nakamura K et al. J Clin Invest 1996: 98: 336-344.
24. Pastore S, Mascia F, Mariani V et al. Ann NY Acad Sci 2002: 973: 210-213.
25. Sabat R, Philipp S, Höflich C et al. Exp Dermatol 2007: 16: 779-798.
26. Won Y H, Sauder D N, McKenzie R C. Br J Dermatol 1994: 130: 312-319.
27. Wei C C, Chen W Y, Wang Y C et al. Clin Immunol 2005: 117: 65-72.
28. Piskin G, Sylva-Steenland R M, Bos J D et al. J Immunol 2006: 176: 1908-1915.
29. Wolk K, Witte E, Warszawska K et al. Eur J Immunol 2009: 39: 3570-3581.